Chemioterapia w raku piersi w Izraelu: proszę uzyskać zestawienie top-3 klinik dla siebie

Leading breast cancer oncologists in Israel combine molecular genetics with personalized chemotherapy to improve patient outcomes. Top specialists like Prof. Ofer Merimsky and Dr. Beatrice Uziely hold international fellowships and lead research at JCI-accredited centers. These experts prioritize genomic testing to tailor aggressive treatments for complex cases.

• Molecular expertise: Dr. Ari Raphael at Sourasky Medical Center leads national genomic medicine initiatives.
• Academic leadership: Dr. Beatrice Uziely at Hadassah Medical Center has authored over 55 research publications.
• Advanced training: Dr. Tamar Jablonski-Perec completed specialized training at Memorial Sloan-Kettering Cancer Center.
• Long-term experience: Dr. Fredi Aviv brings over 30 years of expertise to chemotherapy planning.

Bookimed Expert Insight: Data shows a high concentration of dual-specialized oncologists at Sourasky and Assuta Medical Centers. For instance, Dr. Irina Zhevelyuk and Dr. Irina Stepfansky combine internal medicine with oncology for 25+ years. This allows them to manage chemotherapy side effects while treating the cancer effectively. Patients can access consultations with these experts starting from $750 to $950.

Patient Consensus: Patients note that Israeli oncologists use personalized protocols and early genetic testing to avoid unnecessary treatments. Many were surprised by the meticulous cardiac monitoring required before starting specific chemotherapy cycles. They also appreciate having constant contact with nurses to manage side effects like nausea.

Israeli breast cancer oncologists hold medical degrees followed by five years of specialized residency training. Most maintain board certification from the Scientific Council of the Israel Medical Association. Top specialists often complete international fellowships in the US or Europe to master advanced chemotherapy protocols.

• Specialized training: Doctors complete six years of medical school plus extensive oncology residencies.
• International fellowships: Many specialists trained at institutions like New York Hospital or Institut Gustave Roussy.
• Academic leadership: Senior oncologists often serve as professors or lead national specialized cancer divisions.
• Research expertise: Leading doctors actively participate in global oncology societies and clinical trial groups.

Bookimed Expert Insight: Data shows a trend of dual expertise among top Israeli specialists. For example, Dr. Tamar Sapra at Sourasky Medical Center has 30+ years of experience combining chemotherapy and radiotherapy. This allows for more cohesive treatment plans in one location. Patients often benefit from doctors who hold leadership roles, such as Prof. Ofer Merimsky, who is an Associate Professor and leads a national center.

Patient Consensus: Patients note that doctors are very direct about prognosis and treatment steps. Many appreciate how quickly coordinators organize consultations with specialists who speak fluent English. People were surprised by how daily tumor boards between different doctors made their treatment feel more precise.

Israeli doctors determine the necessity of chemotherapy by integrating advanced genomic profiling with precise tumor biology analysis. Specialized oncologists evaluate hormone receptor status and HER2 protein levels to identify cases where systemic treatment offers the most significant survival benefits.

• Genomic testing: Doctors use Oncotype DX and Prosigna to analyze 21 specific tumor genes.
• Biomarker evaluation: Testing for ER, PR, and HER2 receptors confirms if cancer is triple-negative.
• Recurrence scoring: Low genomic scores help 50% to 70% of early-stage patients skip chemotherapy safely.
• Risk assessment: Teams consider Ki-67 protein levels and lymph node involvement for recurrence risk.

Bookimed Expert Insight: Data shows a strong trend toward genomic-guided medicine led by experts like Dr. Ari Raphael at Sourasky Medical Center. He moderates a Molecular Tumor Board where specialists use liquid biopsies and national genomic initiatives. This high-level coordination allows doctors to customize chemotherapy cycles, often reducing them to four sessions for low-risk cases.

Patient Consensus: Patients note that fresh biomarker testing during second opinions sometimes reverses initial chemotherapy recommendations. They feel relieved when genomic scores show they can rely on hormone therapy alone. Many emphasize that doctors focus heavily on tumor biology rather than just tumor size.

Israeli oncologists routinely provide neoadjuvant chemotherapy to shrink tumors before surgery. This strategic approach often allows for breast-conserving lumpectomies instead of full mastectomies. Specialist doctors use genomic profiling to tailor these systemic treatments for aggressive subtypes like triple-negative or HER2-positive breast cancer.

• Surgical downsizing: Shrinking large tumors increases the likelihood of successful breast-conserving surgery.
• Systemic clearance: Early treatment targets microscopic cancer cells that may have spread elsewhere.
• Response monitoring: Doctors observe how the specific tumor reacts to drugs in real time.
• Pathologic assessment: Achieving a complete response before surgery helps define long-term prognosis.

Bookimed Expert Insight: Data shows that Israeli oncologists often hold dual specializations to refine neoadjuvant plans. For example, Dr. Irina Zhevelyuk at Assuta Medical Center is both an oncologist and a radiologist. This allows for precise coordination between chemotherapy cycles and localized imaging to monitor tumor shrinkage before the surgeon operates.

Patient Consensus: Patients note that starting chemotherapy first does not always mean the cancer is advanced. They feel relieved when scans show the tumor getting smaller before their operation. Many were surprised to find that this strategy could eliminate the need for a mastectomy entirely.

Israeli oncologists utilize standardized breast cancer chemotherapy protocols aligned with NCCN and EORTC benchmarks. Common regimens include AC-T for high-risk cases and TCHP for HER2-positive tumors. Experts often integrate genomic profiling and molecular tumor profiling to personalize systemic treatment and maximize success.

• Adjuvant regimens: AC-T and dose-dense variants are standard to prevent recurrence after surgery.
• HER2-positive protocols: Specialists frequently use TCHP or AC-THP combinations to shrink aggressive tumors.
• Genomic-guided therapy: Dr. Ari Raphael at Sourasky uses molecular profiling to tailor chemotherapy dosage.
• Metastatic treatment: Oncologists apply single-agent options like Capecitabine or Abraxane for advanced stages.

Bookimed Expert Insight: Israeli oncology leads in integrating genomic data into routine care. Dr. Beatrice Uziely at Hadassah Medical Center utilizes molecular profiling to determine if chemotherapy is necessary. This approach allows some patients to avoid intensive systemic treatments entirely while maintaining a high survival rate. Patients can access specialized consultations with Prof. Ofer Merimsky for approximately $950 or Dr. Irina Stepfansky for $750 at Sourasky Medical Center.

Patient Consensus: Patients note that doctors coordinate every step of the journey and provide a clear path forward quickly. Many emphasize that having a dedicated team helps them manage the emotional weight of treatment. They also mention that medical staff often discuss cold caps and fertility preservation before starting the first cycle.

Patients can obtain a second opinion from Israeli breast cancer specialists through remote online consultations or in-person appointments. This process involves submitting medical records to specialized oncology departments for a formal review. Bookimed handles doctor communication and scheduling for these expert assessments.

• Specialist selection: Bookimed matches patients with oncologists based on their specific cancer type.
• Medical records: Patients must provide pathology reports, imaging disks, and previous treatment summaries.
• Consultation delivery: Specialists provide a formal report and treatment plan for local oncology teams.
• Online access: Many senior professors offer video consultations to international patients within weeks.

Bookimed Expert Insight: Data shows that many top Israeli oncologists, such as Prof. Ofer Merimsky and Dr. Irina Stepfansky, hold dual expertise in internal medicine and research. Their active participation in phase I-III clinical trials often allows them to suggest innovative chemotherapy protocols. These specialists typically work at JCI-accredited facilities like Sourasky Medical Center or Assuta Medical Center. Consultations with these leading experts start from $750 to $950.

Patient Consensus: Patients emphasize the importance of having every pathology report and scan ready before the first call. They noticed that identifying a request specifically for a chemotherapy second opinion helps reach the right oncologist faster. Many noted it felt much easier to have a coordinator handle the tricky logistics and translations.